Taisho-controlled pharma giant DHG posts 9.4% net profit surge in 2025

DHG Pharmaceutical JSC (HoSE: DHG), one of the leading pharmaceutical firms in Vietnam, reported audited net profit of VND852 billion ($32.35 million) in 2025, down 5% from its pre-audit figure, as additional tax obligations and provisions weighed on earnings.

After audit adjustments, net profit still rose 9.4% compared to 2024’s VND779 billion ($29.58 million), reflecting steady demand in Vietnam’s pharmaceutical market despite rising regulatory and compliance costs.

According to the audited financial statements, the company recorded net revenue of VND5.27 trillion ($199.97 million), unchanged from earlier disclosures, while gross profit reached VND2.51 trillion ($95.14 million), down slightly by VND6 billion ($227,800).

Despite the downward adjustment, the firm exceeded the year’s profit target by 5%, underscoring resilient operating performance.

The audit highlighted the impact of the parliament’s Resolution 107/2023/QH15, which introduces a 15% global minimum corporate tax rate for large multinational-backed firms.

With Japan’s Taisho Pharmaceutical holding a controlling 51.01% stake, DHG had previously benefited from preferential tax rates below the 15% threshold. This triggered additional tax liabilities under the new mechanism.

As a result, the company booked VND33.01 billion ($1.25 million) in additional corporate tax for 2025, VND21.98 billion ($834,500) in back payments for 2024, and VND1.4 billion ($53,150) paid on behalf of Taisho Vietnam.

Beyond tax adjustments, DHG increased provisions related to environmental obligations. The company set aside an additional VND38.1 billion ($1.45 million) for site restoration and cleanup, bringing total long-term provisions for this purpose to VND81.46 billion ($3.09 million) by end-2025. It also recorded VND4 billion ($151,870) in short-term expenses tied to recycling and packaging treatment.

Separately, total revenue from sales and services surpassed VND6 trillion ($222.8 million) for the first time, reaching VND6.14 trillion ($233 million), up more than 7% year-on-year.

DHG shares ended up 0.3% to VND100,100 ($3.8) each on Tuesday.

  • Related Posts

    Minister JP Nadda launches drug registry to standardise medicine-related information

    Union minister of health and family welfare, Jagat Prakash Nadda launched the Drug Registry as a unified and standardised digital platform for drug-related information to address the issues including confusion…

    Pharmexcil urges companies to adopt NCB voluntary code to prevent chemical diversion into illegal drug production

    The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has urged its member pharma companies to implement the Voluntary Code of Conduct (VCC) introduced by the Narcotics Control Bureau (NCB) to…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Minister JP Nadda launches drug registry to standardise medicine-related information

    Minister JP Nadda launches drug registry to standardise medicine-related information

    Pharmexcil urges companies to adopt NCB voluntary code to prevent chemical diversion into illegal drug production

    Pharmexcil urges companies to adopt NCB voluntary code to prevent chemical diversion into illegal drug production

    Govt review finds no common thread in post-delivery deaths

    Gurgaon call centre busted for cheating people with fake weight-loss products, 3 women held

    Gurgaon call centre busted for cheating people with fake weight-loss products, 3 women held

    Madhya Pradesh toddler loses vision after doctor administers drops, probe underway

    Madhya Pradesh toddler loses vision after doctor administers drops, probe underway

    CDSCO Mandates SUGAM Portal for Post-Approval Changes (PAC) to Vaccine and Anti-Sera Import Licences

    CDSCO Mandates SUGAM Portal for Post-Approval Changes (PAC) to Vaccine and Anti-Sera Import Licences